These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34069029)

  • 21. Ca2+-permeable TRPV1 pain receptor knockout rescues memory deficits and reduces amyloid-β and tau in a mouse model of Alzheimer's disease.
    Kim J; Lee S; Kim J; Ham S; Park JHY; Han S; Jung YK; Shim I; Han JS; Lee KW; Kim J
    Hum Mol Genet; 2020 Jan; 29(2):228-237. PubMed ID: 31814000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.
    Ke YD; Delerue F; Gladbach A; Götz J; Ittner LM
    PLoS One; 2009 Nov; 4(11):e7917. PubMed ID: 19936237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse.
    Ontiveros-Torres MÁ; Labra-Barrios ML; Díaz-Cintra S; Aguilar-Vázquez AR; Moreno-Campuzano S; Flores-Rodríguez P; Luna-Herrera C; Mena R; Perry G; Florán-Garduño B; Luna-Muñoz J; Luna-Arias JP
    J Alzheimers Dis; 2016 Mar; 52(1):243-69. PubMed ID: 27031470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
    Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
    Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.
    Morin JP; Cerón-Solano G; Velázquez-Campos G; Pacheco-López G; Bermúdez-Rattoni F; Díaz-Cintra S
    J Alzheimers Dis; 2016; 51(1):69-79. PubMed ID: 26836189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer's disease.
    Feld M; Krawczyk MC; Sol Fustiñana M; Blake MG; Baratti CM; Romano A; Boccia MM
    J Alzheimers Dis; 2014; 40(1):69-82. PubMed ID: 24334722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.
    Chalermpalanupap T; Schroeder JP; Rorabaugh JM; Liles LC; Lah JJ; Levey AI; Weinshenker D
    J Neurosci; 2018 Jan; 38(1):74-92. PubMed ID: 29133432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Niehoff ML; Morley JE; Jelsing J; Pyke C; Knudsen LB; Farr SA; Vrang N
    J Alzheimers Dis; 2015; 46(4):877-88. PubMed ID: 25869785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fuzhisan ameliorates Aβ production and tau phosphorylation in hippocampal of 11month old APP/PS1 transgenic mice: A Western blot study.
    Zhang ZX; Zhao RP; Wang DS; Wang AN
    Exp Gerontol; 2016 Nov; 84():88-95. PubMed ID: 27612601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
    Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
    Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
    Tackenberg C; Kulic L; Nitsch RM
    PLoS One; 2020; 15(9):e0239584. PubMed ID: 32966331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
    Dunys J; Valverde A; Checler F
    J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
    Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
    Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.
    Arner A; Rockenstein E; Mante M; Florio J; Masliah D; Salehi B; Adame A; Overk C; Masliah E; Rissman RA
    J Alzheimers Dis; 2018; 61(3):1201-1219. PubMed ID: 29332037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential accumulation of Tau phosphorylated at residues Thr231, Ser262 and Thr205 in hippocampal interneurons and its modulation by Tau mutations (VLW) and amyloid-β peptide.
    Dávila-Bouziguet E; Targa-Fabra G; Ávila J; Soriano E; Pascual M
    Neurobiol Dis; 2019 May; 125():232-244. PubMed ID: 30553886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis.
    Terron HM; Parikh SJ; Abdul-Hay SO; Sahara T; Kang D; Dickson DW; Saftig P; LaFerla FM; Lane S; Leissring MA
    Alzheimers Res Ther; 2024 Apr; 16(1):70. PubMed ID: 38575959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
    Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
    Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.